Robert Bosch Krankenhaus

Futó vizsgálatok

• Toboroz

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· 3. fázis· Forrás

• Toboroz

  ColoReg: A Register for Gastrointestinal Endoscopy Reports and Examination Videos

  NCT06920680· Forrás

• Toboroz

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· 3. fázis· Forrás

• Toboroz

  Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

  NCT05114850· Forrás

• Toboroz

  The German ADPKD Tolvaptan Treatment Registry

  NCT02497521· Forrás

• Toboroz

  GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

  NCT02872987· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Akut limfoid leukémia (ALL)1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Policisztás vesebetegség1 toboroz
• Szívelégtelenség1 toboroz
• Tüdőrák1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· 3. fázis· Forrás

• Lezárult

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· 3. fázis· Forrás

• Lezárult

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· 3. fázis· Forrás

• Lezárult

  Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML

  NCT02461537· 3. fázis· Forrás